Navigation Links
BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
Date:8/15/2013

Fayetteville, Arkansas (PRWEB) August 15, 2013

BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,450,273, entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone," to The Board of Trustees of the University of Arkansas (U.S.), the Oschner Clinic Foundation (U.S.) and the National University Corporation Kagawa University (Japan). BiologicsMD™ is the exclusive licensee of the patent. The patent claims various forms of composition of matter for the proteins derived by the fusion between collagen-binding polypeptides bound to parathyroid hormone receptor agonists.

BiologicsMD is developing PTH-CBD™ as a novel and unique treatment for osteoporosis and other bone-related disorders. The technology originated in the laboratories of Joshua Sakon, Ph.D. (University Of Arkansas), Robert Gensure, M.D., Ph.D. (previously with the Oschner Clinic and currently with Montefiore Medical Center, NYC) and Osamu Matsushita, Ph.D. (previously with Kagawa University and currently with Okayama University).

"This is the first U.S. patent to issue from a patent family related to PTH-CBD and its use in treating diseases of the bone and other collagen-related disorders," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has pending methods patent applications in the U.S., along with patents being pursued in major worldwide markets. Because of PTH-CBD’s unique profile of selective targeting and other pharmacologic properties, we foresee a highly differentiated new product to help treat human disease.”

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11030677.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Micropharma Limited announces new agreement to commercialize novel natural health products
2. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
3. WuXi PharmaTech Announces Second-Quarter 2013 Results
4. Charm Sciences, Inc. Announces Charm® FAST PHAGE Method Accepted by EPA for Detection of Coliphage in Ground Water
5. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
6. BCA Announces a New Member Joins Its Blood Center Coperative
7. BioLife Solutions Announces Record Revenue of $2.3 Million in the Second Quarter of 2013
8. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
9. Vivid Learning Systems Announces Newly Designed Industry Websites for MSHA, Electrical Utility Safety, Healthcare and OSHA Compliance
10. Nanounity Announces That the Delmic SECOM Correlative Microscopy System Has Won a 2013 Microscopy Today Innovation Award.
11. Natural Acne Remedy, Probiotic Action, Announces the Unveiling of their New Probiotic Acne Cleanser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... Jupiter, FL (PRWEB) , ... October 09, 2017 , ... ... episode, scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on ... Agriculture industry is faced with the challenge of how to continue to feed a ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the ... and accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their ...
Breaking Biology Technology:
(Date:8/15/2017)... Va. , Aug. 15 2017   ivWatch LLC , ... of intravenous (IV) therapy, today announced receipt of its ISO 13485 ... developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the ... "This is ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
Breaking Biology News(10 mins):